What is the long-term durability of the benefits of the different DCBs: What is the value of spot stenting of residual stenoses with DCBs?

Gunnar Tepe, MD
RoMed Clinic, Rosenheim, Germany

Disclosures

Study support by BART, Bayer, B Braun, Biotronic, Gore, Phillips, Medtronic, Shockwave, Verian

Multicenter RCTs of FDA Approved DCBs
Primary Patency by Kaplan-Meier Estimates, ITT Basis

Clinical Evidence – Global Registries

IN.PACT Global Study
Stented vs Non-Stented Analysis

Freedom from CD-TLR Through 2 Years
Conclusion on 1st question

- DCBs with (different) benefit compared to POBA after 2y
- In.Pact DCB with sustained benefit up to 5y
- With increased length and complexity more stents needed
- Bail out Stent + DCB with same patency as DCB alone….but what about spot stenting?

DCB + whole lesion with stent

DCB + spot stenting

Spot Stenting Evidence

Spot Stenting Evidence

LOCOMOTIVE study

12 month results (N=75)

TLR: 9.3% at 12 months (n=75)
TASC C/D lesions: 51.1%
Procedural success: 100%
Primary Patency: 85.7%
Mean lesion length: 14.5 cm
Lesion length saved from stenting: 47.0%

Conclusion on 2nd question

- DCB + whole lesion coverage with stent might fail because of stent fractures
- DCB + spot stent might preferred
- Studies mandatory